Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

John Imig to Epoxide Hydrolases

This is a "connection" page, showing publications John Imig has written about Epoxide Hydrolases.

 
Connection Strength
  
 
 
10.616
  
  1. Imig JD, Cervenka L, Neckar J. Epoxylipids and soluble epoxide hydrolase in heart diseases. Biochem Pharmacol. 2022 01; 195:114866.
    View in: PubMed
    Score: 0.773
  2. Stavniichuk A, Hye Khan MA, Yeboah MM, Chesnik MA, Jankiewicz WK, Hartmann M, Bl?cher R, Kircher T, Savchuk O, Proschak E, Imig JD. Dual soluble epoxide hydrolase inhibitor/PPAR-? agonist attenuates renal fibrosis. Prostaglandins Other Lipid Mediat. 2020 10; 150:106472.
    View in: PubMed
    Score: 0.699
  3. Imig JD. Epigenetic soluble epoxide hydrolase regulation causes endothelial dysfunction. Acta Physiol (Oxf). 2019 01; 225(1):e13203.
    View in: PubMed
    Score: 0.623
  4. Hye Khan MA, Kolb L, Skibba M, Hartmann M, Bl?cher R, Proschak E, Imig JD. A novel dual PPAR-? agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia. 2018 10; 61(10):2235-2246.
    View in: PubMed
    Score: 0.612
  5. Hye Khan MA, Hwang SH, Sharma A, Corbett JA, Hammock BD, Imig JD. A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat. Prostaglandins Other Lipid Mediat. 2016 09; 125:40-7.
    View in: PubMed
    Score: 0.532
  6. Imig JD, Walsh KA, Hye Khan MA, Nagasawa T, Cherian-Shaw M, Shaw SM, Hammock BD. Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor ? agonist improve vascular function and decrease renal injury in hypertensive obese rats. Exp Biol Med (Maywood). 2012 Dec; 237(12):1402-12.
    View in: PubMed
    Score: 0.414
  7. Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev. 2012 Jan; 92(1):101-30.
    View in: PubMed
    Score: 0.388
  8. Elmarakby AA, Faulkner J, Al-Shabrawey M, Wang MH, Maddipati KR, Imig JD. Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. Am J Physiol Regul Integr Comp Physiol. 2011 Nov; 301(5):R1307-17.
    View in: PubMed
    Score: 0.378
  9. Imig JD. Targeting epoxides for organ damage in hypertension. J Cardiovasc Pharmacol. 2010 Oct; 56(4):329-35.
    View in: PubMed
    Score: 0.356
  10. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009 Oct; 8(10):794-805.
    View in: PubMed
    Score: 0.332
  11. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol. 2009 Sep; 297(3):F740-8.
    View in: PubMed
    Score: 0.326
  12. Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai HJ, Hammock BD, Imig JD. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol. 2009 Jun; 174(6):2086-95.
    View in: PubMed
    Score: 0.324
  13. Olearczyk JJ, Quigley JE, Mitchell BC, Yamamoto T, Kim IH, Newman JW, Luria A, Hammock BD, Imig JD. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond). 2009 Jan; 116(1):61-70.
    View in: PubMed
    Score: 0.316
  14. Olearczyk JJ, Field MB, Kim IH, Morisseau C, Hammock BD, Imig JD. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. J Pharmacol Exp Ther. 2006 Sep; 318(3):1307-14.
    View in: PubMed
    Score: 0.264
  15. Imig JD. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev. 2006; 24(2):169-88.
    View in: PubMed
    Score: 0.256
  16. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2005 Dec; 46(6):842-8.
    View in: PubMed
    Score: 0.255
  17. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 2005 Oct; 46(4):975-81.
    View in: PubMed
    Score: 0.251
  18. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol. 2005 Sep; 289(3):F496-503.
    View in: PubMed
    Score: 0.250
  19. Zhao X, Dey A, Romanko OP, Stepp DW, Wang MH, Zhou Y, Jin L, Pollock JS, Webb RC, Imig JD. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol Regul Integr Comp Physiol. 2005 Jan; 288(1):R188-96.
    View in: PubMed
    Score: 0.234
  20. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol. 2004 May; 15(5):1244-53.
    View in: PubMed
    Score: 0.228
  21. Khan MAH, Nolan B, Stavniichuk A, Merk D, Imig JD. Dual soluble epoxide hydrolase inhibitor - farnesoid X receptor agonist interventional treatment attenuates renal inflammation and fibrosis. Front Immunol. 2023; 14:1269261.
    View in: PubMed
    Score: 0.223
  22. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002 Feb; 39(2 Pt 2):690-4.
    View in: PubMed
    Score: 0.195
  23. Imig JD, Jankiewicz WK, Khan AH. Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture. Hypertension. 2020 07; 76(1):3-15.
    View in: PubMed
    Score: 0.174
  24. Cert?kov? Ch?bov? V, Kujal P, Vanourkov? Z, ?karoupkov? P, Sadowski J, Kompanowska-Jezierska E, Tesar V, Hammock B, Imig J, Maxov? H, Cervenka L, Vaneckov? I. Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats. Kidney Blood Press Res. 2019; 44(6):1493-1505.
    View in: PubMed
    Score: 0.168
  25. Hye Khan MA, Schmidt J, Stavniichuk A, Imig JD, Merk D. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. Biochem Pharmacol. 2019 08; 166:212-221.
    View in: PubMed
    Score: 0.162
  26. Cert?kov? Ch?bov? V, Kujal P, ?karoupkov? P, Varnourkov? Z, Vackov? ?, Huskov? Z, Kikerlov? S, Sadowski J, Kompanowska-Jezierska E, Baranowska I, Hwang SH, Hammock BD, Imig JD, Tesar V, Cervenka L. Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. Kidney Blood Press Res. 2018; 43(2):329-349.
    View in: PubMed
    Score: 0.149
  27. Bettaieb A, Koike S, Hsu MF, Ito Y, Chahed S, Bachaalany S, Gruzdev A, Calvo-Rubio M, Lee KSS, Inceoglu B, Imig JD, Villalba JM, Zeldin DC, Hammock BD, Haj FG. Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia. Biochim Biophys Acta Gen Subj. 2017 Nov; 1861(11 Pt A):2758-2765.
    View in: PubMed
    Score: 0.143
  28. Sporkov? A, J?chov? S, Huskov? Z, Kopkan L, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kramer HJ, Cervenka L. Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharmacol Physiol. 2014 Dec; 41(12):1003-13.
    View in: PubMed
    Score: 0.119
  29. Kim J, Yoon SP, Toews ML, Imig JD, Hwang SH, Hammock BD, Padanilam BJ. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. Am J Physiol Renal Physiol. 2015 Jan 15; 308(2):F131-9.
    View in: PubMed
    Score: 0.118
  30. Kim J, Imig JD, Yang J, Hammock BD, Padanilam BJ. Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation. Am J Physiol Renal Physiol. 2014 Oct 15; 307(8):F971-80.
    View in: PubMed
    Score: 0.117
  31. Kujal P, Cert?kov? Ch?bov? V, ?karoupkov? P, Huskov? Z, Vernerov? Z, Kramer HJ, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kitada K, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Cervenka L. Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. Clin Exp Pharmacol Physiol. 2014 Mar; 41(3):227-37.
    View in: PubMed
    Score: 0.113
  32. Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Iosif AM, Liu JY, Weiss RH, Chiamvimonvat N, Imig JD, Hammock BD. Anti-inflammatory effects of ?-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol. 2013 Sep; 62(3):285-97.
    View in: PubMed
    Score: 0.109
  33. Varcabova S, Huskova Z, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Kitada K, Cervenka L. Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system. Clin Exp Pharmacol Physiol. 2013 Apr; 40(4):273-81.
    View in: PubMed
    Score: 0.106
  34. Honetschl?gerov? Z, Kitada K, Huskov? Z, Sporkov? A, Kopkan L, B?rgelov? M, Varcabov? ?, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerov? Z, Cervenka L. Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. J Hypertens. 2013 Feb; 31(2):321-32.
    View in: PubMed
    Score: 0.105
  35. Imig JD. Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug; 104-105:2-7.
    View in: PubMed
    Score: 0.104
  36. Kopkan L, Huskov? Z, Sporkov? A, Varcabov? ?, Honetschl?gerov? Z, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Kramer HJ, B?rgelov? M, Vojt?kov? A, Kujal P, Vernerov? Z, Cervenka L. Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension. Kidney Blood Press Res. 2012; 35(6):595-607.
    View in: PubMed
    Score: 0.102
  37. Neck?r J, Kopkan L, Huskov? Z, Kol?r F, Papou?ek F, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Mal? J, Netuka I, O?t?dal B, Cervenka L. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clin Sci (Lond). 2012 Jun; 122(11):513-25.
    View in: PubMed
    Score: 0.100
  38. Honetschl?gerov? Z, Sporkov? A, Kopkan L, Huskov? Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerov? Z, Ch?bov? VC, Tesar V, Cervenka L. Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2011 Aug; 29(8):1590-601.
    View in: PubMed
    Score: 0.094
  39. Gauthier KM, Olson L, Harder A, Isbell M, Imig JD, Gutterman DD, Falck JR, Campbell WB. Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles. Am J Physiol Renal Physiol. 2011 Oct; 301(4):F765-72.
    View in: PubMed
    Score: 0.094
  40. Luria A, Bettaieb A, Xi Y, Shieh GJ, Liu HC, Inoue H, Tsai HJ, Imig JD, Haj FG, Hammock BD. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A. 2011 May 31; 108(22):9038-43.
    View in: PubMed
    Score: 0.093
  41. Honetschl?gerov? Z, Huskov? Z, Vanourkov? Z, Sporkov? A, Kramer HJ, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Cervenka L, Kopkan L. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J Physiol. 2011 Jan 01; 589(Pt 1):207-19.
    View in: PubMed
    Score: 0.091
  42. Imig JD. Eicosanoids and renal damage in cardiometabolic syndrome. Expert Opin Drug Metab Toxicol. 2008 Feb; 4(2):165-74.
    View in: PubMed
    Score: 0.074
  43. Falck JR, Koduru SR, Mohapatra S, Manne R, Atcha KR, Atcha R, Manthati VL, Capdevila JH, Christian S, Imig JD, Campbell WB. 14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications. J Med Chem. 2014 Aug 28; 57(16):6965-72.
    View in: PubMed
    Score: 0.029
  44. Sporkov? A, Kopkan L, Varcabov? S, Huskov? Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Cervenka L. Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2011 Jun; 300(6):R1468-75.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.